Individual Investors in Zhejiang Medicine Co., Ltd. (SHSE:600216) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.9% Last Week
Individual Investors in Zhejiang Medicine Co., Ltd. (SHSE:600216) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.9% Last Week
Key Insights
主要見解
- Significant control over Zhejiang Medicine by individual investors implies that the general public has more power to influence management and governance-related decisions
- The top 25 shareholders own 46% of the company
- Past performance of a company along with ownership data serve to give a strong idea about prospects for a business
- 個人投資者對浙江醫藥的重要控制權意味着普通公衆對於管理和治理相關決策有更大的影響力。
- 前 25 名股東擁有該公司的 46%。
- 公司過去的業績以及所有權數據,有助於形成對業務前景的強烈想法。
To get a sense of who is truly in control of Zhejiang Medicine Co., Ltd. (SHSE:600216), it is important to understand the ownership structure of the business. We can see that individual investors own the lion's share in the company with 53% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
要想真正了解浙江醫藥股份有限公司(上海證券交易所股票代碼:600216)的控制權歸屬,了解商業公司的所有權結構是很重要的。我們可以看到個人投資者擁有該公司53%的所有權。這意味着,該群體在股票上漲時獲得最大利益(在下跌時則損失最大)。
Clearly, individual investors benefitted the most after the company's market cap rose by CN¥546m last week.
顯然,上週浙江醫藥的市值上漲了人民幣54600萬元,其中個人投資者獲益最多。
Let's take a closer look to see what the different types of shareholders can tell us about Zhejiang Medicine.
讓我們更近距離地觀察一下不同類型的股東對於浙江醫藥有什麼樣的啓示。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240622/0-bba1c93cd3f1578f36defa87628a7b0e-0-6ad6434f2575e84f80361a94f5632d32.png/big)
What Does The Institutional Ownership Tell Us About Zhejiang Medicine?
機構持股向我們傳遞了關於浙江醫藥的哪些信息?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構通常在向自己的投資者報告時會針對一個基準進行衡量,因此一旦某隻股票被納入主要指數,他們通常會更加熱衷於該股票。我們預計大多數公司都會有一些機構在登記簿上,尤其是那些正在增長的公司。
Zhejiang Medicine already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Zhejiang Medicine's historic earnings and revenue below, but keep in mind there's always more to the story.
浙江醫藥股份有限公司的股權登記簿上已經有了機構的身影,機構持有該公司的股票,這表明投資界普遍認爲該公司有一定的信譽。然而,完全依賴於機構型投資者所帶來的所謂認可是比較危險的。他們也會犯錯誤。當多個機構持有某隻股票時,存在他們會進行“擁擠交易”的風險,一旦這種交易失敗,多方將快速舉行拋售並爭奪股票的風險就會更高。這種風險在一家沒有成長曆史的公司中更高。你可以在下方查看浙江醫藥的歷史收益和營業收入,但要記住,故事總會有更多的版本。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240622/0-bba1c93cd3f1578f36defa87628a7b0e-1-8b092b379972b98e9094bf06ec1e5769.png/big)
Zhejiang Medicine is not owned by hedge funds. Xinchang Changxin Investment Development Ltd. is currently the largest shareholder, with 22% of shares outstanding. In comparison, the second and third largest shareholders hold about 16% and 1.8% of the stock.
浙江醫藥並沒有被對沖基金持有,新昌長新投資發展有限公司目前是最大的股東,持有22%的股份。相比之下,第二和第三大股東分別持有該股的16%和1.8%。
A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.
對我們的所有權數據進行更深入的研究表明,前25名股東的持股總額不到註冊表的一半,表明有一個小股東的大群體,其中沒有單個股東擁有多數股份。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.
雖然研究公司的機構持股可以增加您的研究價值,但研究分析師的建議以加深對股票預期表現的全面了解也是一個好習慣。雖然有部分分析師的覆蓋,但該公司可能沒有受到廣泛的關注。因此,在未來可能會受到更多關注。
Insider Ownership Of Zhejiang Medicine
浙江醫藥內部股權情況
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
在不同國家,內部人員的定義可能會略有不同,但董事會成員始終是內部人員。管理層最終向董事會負責。然而,如果管理人員是創始人或CEO,那麼成爲執行董事會成員也是很常見的。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。
Our most recent data indicates that insiders own less than 1% of Zhejiang Medicine Co., Ltd.. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around CN¥38m worth of shares (at current prices). It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.
我們最近的數據顯示,內部人持有浙江醫藥股份有限公司的股份不到1%。但是,我們注意到內部人可能會通過私人公司或其他公司機構間接持有股權。它實際上是一家相當大的公司,董事會成員可以擁有公司較大的股權,但在這種情況下,他們持有最多價值人民幣3800萬元的股票(按照現價計算)。看到至少有一些內部人持股總是好的,但值得檢查他們是否一直在出售。
General Public Ownership
一般大衆所有權
The general public, who are usually individual investors, hold a substantial 53% stake in Zhejiang Medicine, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.
普通公衆,通常是個人投資者,持有浙江醫藥的53%的股權,這意味着這是一隻相當受歡迎的股票。這種持股數量賦予普通公衆一定的集體權力,他們可以並且很可能會影響高層薪酬、紅利政策以及擬議中的業務收購決策。
Private Equity Ownership
股權投資公司持有8.8%的股份,有能力參與塑造以價值創造爲重點的公司策略。一些投資者可能會因此而受到鼓舞,因爲股權投資公司有時可以鼓勵市場看到公司的價值,從而採取有益的策略。另外,那些持有者可能在將其上市後退出投資。
Private equity firms hold a 16% stake in Zhejiang Medicine. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
股權投資公司持有浙江醫藥16%的股權,這表明他們在重要政策決策上能夠發揮影響力。有些人可能會喜歡這一點,因爲股權投資公司有時是持有管理公司負責人的激進派。但是,有時候私人股權公司也會退出並使公司上市。
Private Company Ownership
私有公司的所有權
It seems that Private Companies own 24%, of the Zhejiang Medicine stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
似乎私人公司持有浙江醫藥24%的股權。私人公司可能是相關方。有時候,內部人物通過持有私人公司的股權而不是以個人身份持有上市公司的股權。雖然很難得出任何廣泛的結論,但值得注意的是,這是進一步研究的領域。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Zhejiang Medicine better, we need to consider many other factors. Be aware that Zhejiang Medicine is showing 2 warning signs in our investment analysis , you should know about...
始終值得考慮公司的不同股東群體,但是要更好地了解浙江醫藥,我們需要考慮許多其他因素。請注意,根據我們的投資分析表明,浙江醫藥存在兩個警示信號,你應該知道...
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但最終,決定該業務所有者將獲得多大利益的是未來而非過去。因此,我們認爲最好查看此免費報告,以了解分析師是否預測更光明的未來。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com